Evercore ISI upgraded Fortrea (FTRE) to Outperform from In Line with a price target of $25, up from $14. The firm cites the “accelerating” biopharma cycle and the company’s improved performance for the upgrade. Fortrea is seeing higher revenue and margins versus consensus estimates, and is also benefiting from deleveraging, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE: